Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) EBT (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed EBT for 3 consecutive years, with -$35.3 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT rose 19.62% to -$35.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$155.1 million, a 109.44% decrease, with the full-year FY2024 number at $1.7 billion, up 803.97% from a year prior.
  • EBT was -$35.3 million for Q3 2025 at Inhibrx Biosciences, down from -$28.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $1.9 billion in Q2 2024 to a low of -$92.0 million in Q4 2023.
  • A 3-year average of $139.8 million and a median of -$43.6 million in 2024 define the central range for EBT.
  • Peak YoY movement for EBT: skyrocketed 4873.32% in 2024, then tumbled 101.54% in 2025.
  • Inhibrx Biosciences' EBT stood at -$92.0 million in 2023, then skyrocketed by 47.96% to -$47.9 million in 2024, then increased by 26.34% to -$35.3 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's EBT are -$35.3 million (Q3 2025), -$28.7 million (Q2 2025), and -$43.3 million (Q1 2025).